Admission to Apex segment of AQSE Growth Market

EDX Medical Group PLC

24 April 2024

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended.  On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Admission to the Apex segment of the AQSE Growth Market

EDX Medical Group plc · EDX

24th April 2024

EDX Medical Group plc (AQSE: EDX) ("EDX Medical" or the "Company"), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, is pleased to announce that it's ordinary shares are now eligible to commence trading on the Apex segment of the Aquis Stock Exchange ("AQSE") with effect from Monday, 29^th April, 2024.

The Apex segment is reserved for larger, more established businesses with a proven growth strategy and which meet high standards of corporate governance. These strict eligibility criteria include having at least 25% of shares in public hands, a minimum of 25 shareholders and a two-year consolidated trading history and compliance with the QCA Code or the UK corporate governance code. 

Dr Mike Hudson, CEO, EDX Medical Group plc, said:

"We are delighted to become part of the Apex segment on the Aquis Stock Exchange. This move reflects the success of our growth strategy since admission to the market in November 2022 and the evolution of our business.  We were particularly pleased with the support from investors during our successful fund raising earlier this year which enables us to accelerate our product development programme.  Our move to the Apex segment will provide further visibility for investors, and we welcome the increased emphasis on transparency, liquidity, and corporate governance, which align strongly with our own values."

Alasdair Haynes, CEO, Aquis Exchange plc, said:

"We are delighted to see EDX Medical move up to the Apex segment of the Aquis Stock Exchange Growth Market. It's fantastic to see how the company has progressed so far, and I am proud that Aquis can offer a tailored experience for growth companies that allows for increased exposure to investors at appropriate stages."

The board of directors of EDX Medical plc accept responsibility for this announcement.

ENDS

Contacts:

EDX Medical plc
Dr Mike Hudson (Chief Executive Officer)	[phone]
Oberon Capital
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)	[phone]
Media House International
Ramsay Smith Gary McQueen	[phone] [e-mail] + 44 (0)7834 694609 [e-mail]

Notes for Editors:

About EDX Medical Group www.edxmedical.com  

EDX Medical Group Plc develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease and infectious diseases. The company is now listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group operates a molecular biology and diagnostics laboratory in Cambridge, UK, and 100%-owned subsidiaries "Hutano Diagnostics Ltd", based in Oxford and "Torax Biosciences Ltd" in Ireland which together are pioneering the development of novel point of care tests.  

EDX Medical conducts test development and product validation to ISO 13485 and provides testing and genomic sequencing services accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

 

END